
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Eric Simpson explains how both clinical and subclinical disease control are critical for achieving true disease modification in atopic dermatitis, emphasizing the role of biomarkers in predicting long-term outcomes and guiding treatment decisions.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
In recognition of World Digestive Health Day, ADVENT is providing medical education resources to increase awareness of eosinophilic esophagitis (EoE).

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.
Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.
In this hypothetical EoE patient case, learn about the different disease domains that are important in seeing the complete patient picture in EoE.
Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.

Highlights from the ADVENT symposium at the 2023 World Congress of Dermatology in Singapore.

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.
Prof. Salvatore Oliva discusses the latest treatment options for adolescents and adults with EoE and the importance of effective transition of care.